A new non-invasive standard for fibrosis screening.
ScarDx is developing software designed to support non-invasive fibrosis assessment, beginning with kidney fibrosis.
Software that helps ultrasound measure organ scarring.
ScarDx is developing software designed to make fibrosis assessment faster, safer, and more scalable than biopsy-centered workflows.
Fibrosis is common, but assessment still depends too often on a biopsy.
Across kidney and liver disease, fibrosis is a major endpoint. Current pathways often rely on biopsy—an invasive, costly approach that is difficult to repeat and vulnerable to sampling error.
The need for a safe, accurate, and scalable alternative
- Fibrosis is central to disease progression across major organ systems.
- Biopsy remains invasive, risky, and difficult to scale in routine care and trials.
- Clinicians, patients, and pharma all need repeatable non-invasive assessment.
A software-first fibrosis imaging platform.
ScarDx is developing an ultrasound software platform intended to support quick, accurate, cost-effective, and non-invasive fibrosis assessment.
Our flagship ScarScan software has been validated in first-in-human studies
- First-in-the-world Nature Medicine clinical trial.
- Kidney fibrosis imaging is our initial goal.
- Future plans include adaptation for liver imaging.
Led by world experts in kidney disease and quantitative ultrasound
ScarDx brings together clinical insight into fibrosis with technical leadership in imaging physics and advanced ultrasound analysis.
Dr. Darren Yuen, MD/PhD
Canada Research Chair in Fibrotic InjuryPracticing nephrologist with direct access to biopsies and imaging, deep fibrosis domain expertise, and academic and clinical leadership in fibrotic injury.
Dr. Eno Hysi, PhD
Canada Research Chair in Quantitative Ultrasound and Photoacoustic ImagingImaging physics expert leading the technical algorithmic developments, with extensive experience in translational imaging trials and biomedical physics
Common questions about ScarDx.
A quick overview for investors, collaborators, and future team members.
What problem does ScarScan solve?
ScarScan enables easy, rapid, and non-invasive fibrosis assessment. Currently, the only way to measure kidney fibrosis is via a biopsy, which is risky, takes at least 1 - 2 days for results, and is prone to sampling bias.
Who is the product for?
ScarScan is built for clinicians, pharma, researchers, and ultrasound manufacturers as a transformative solution for non-invasive fibrosis imaging.
Why ultrasound?
Ultrasound is widely available, cost effective, and scalable. ScarScan software unlocks fibrosis imaging capacity that traditional ultrasound has failed to capture.
How will the platform be validated?
ScarScan is being validated in human trials against gold standard biopsy data.